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Abstract  
Angiogenesis is the development of blood vessels from existing vasculature via sprouting 
of endothelial cells. It is regulated by growth factor signals including Bone Morphogenetic 
Protein (BMP), a member of the TGFβ superfamily of signaling pathways. The BMP ligand 
leads to intracellular signaling and response via engagement with the heterotetrameric BMP 
receptor on the surface of an endothelial cell (EC). The receptor complex phosphorylates 
intracellular SMAD1/5/8 proteins. These proteins then bind to SMAD4 protein to facilitate 
nuclear translocation and transcriptional regulation.5 The Notch signaling pathway has been 
shown to downregulate EC responsiveness to BMP signaling by mechanisms that are not fully 
understood.6 A screen to investigate Notch-regulated BMP/TGFβ pathway members identified 
several proteins, including PMEPA1 and SMAD7, that are upregulated by Notch signaling and 
negatively regulate TGFβ signaling.5,9 PMEPA1 inhibition of BMP signaling is unknown in EC, 
so we sought to determine PMEPA1 function in EC. Knockdown of PMEPA1 expression 
significantly increased signaling in response to BMP ligand, indicating that PMEPA1 inhibits 
BMP signaling in endothelial cells. SMAD7 is a known inhibitor of TGFβ signaling; however, 
we found that SMAD7 knockdown did not affect BMP responsiveness of EC. Preliminary results 
from experiments designed to test the effect of reduced levels of PMEPA1 or SMAD7 in a 3D 
blood vessel formation sprouting assay indicate that neither PMEPA1 nor SMAD7 have a strong 
effect on 3D angiogenesis. We hypothesize that PMEPA1 modulates the responsiveness of 
endothelial cells to BMP by virtue of their Notch status. Understanding the function of these 
Notch-regulated BMP/TGFβ pathway inhibitors expressed by EC is important, as they hold 
therapeutic potential for diseases of aberrant BMP signaling.8 
      
  
Introduction 
Angiogenesis, the growth of new blood vessels from preexisting vasculature, is a key 
process in development, wound healing, and other physiological processes. It involves tip cell 
activation, vessel sprouting, fusion, and lumen formation. Angiogenesis is regulated by several 
growth factor signal transduction pathways, such as the Bone Morphogenetic Protein (BMP) 
signaling, a member of the TGFβ superfamily of signaling pathways. Improper regulation of 
BMP signaling has been linked to various human cardiovascular pathologies, including 
pulmonary arterial hypertension (PAH), hereditary hemorrhagic telangiectasia (HHT), and 
cerebral cavernous malformations (CCM).8 In BMP and TGFβ signaling, stimulation by ligands 
initiates formation of a heterotetrameric receptor complex composed of two type I and two type 
II receptors. Type II receptors then phosphorylate Type I receptors, which in turn phosphorylate 
intracellular receptor SMAD (RSMAD) proteins. Inhibitory SMADs such as SMAD6/7 
antagonize TGFβ signaling by blocking R-SMAD phosphorylation. These phosphorylated 
SMADs (pSMADs) then bind to co-SMAD4 and translocate to the nucleus to regulate 
transcription and vessel sprouting.5 
 
The BMP ligands BMP2 and BMP6 have been shown to induce sprouting angiogenesis 
in vitro in a 3-dimensional blood vessel formation assay.6 These ligands have also been shown to 
induce vein-specific angiogenesis in vivo. The use of a heat-shock inducible promoter upstream 
of bmp2b in zebrafish and subsequent induced overexpression of the construct caused increased 
angiogenesis in the caudal vein plexus, but not from the axial vein.10 These data indicate that 
BMP signaling via BMP6 and BMP2 is potently pro-angiogenic in vivo. 
 
Additionally, the response of endothelial cells (EC) to BMP is tunable depending on the 
Notch status of the surrounding environment. Previous studies have shown that Notch 
downregulates the response of EC to BMP ligands via upregulation of the inhibitory SMAD, 
SMAD6.6 However, a screen to identify other BMP/TGFβ members that are regulated by Notch 
signaling revealed two proteins, Prostate Transmembrane Protein, Androgen Induced 1 
(PMEPA1) and Mothers Against Decapentaplegic Homolog 7 (SMAD7), whose expression 
levels are significantly upregulated in the presence of Notch ligand. While these proteins are 
both known inhibitors of TGFβ signaling, and SMAD7 inhibits BMP signaling in some cell 
lines, their role in BMP signaling and EC has not yet been studied. 
 
One protein, SMAD7, negatively regulates both TGFβ and BMP signaling via 
sequestration of intracellular receptor SMAD proteins and prevents their phosphorylation.5 
PMEPA1 is a transmembrane protein also thought to act in a similar manner by sequestering 
TGFβ RSMAD proteins (SMAD2/3)9 and, therefore, may interact with structurally similar BMP 
RSMAD 1/5/8 proteins. PMEPA1 also recruits ubiquitin ligases to the type I TGFβ receptor, but 
interactions with the analogous BMP receptors have not been examined.1 Existing evidence 
indicates that PMEPA1 and SMAD7 inhibit TGFβ signaling, which shares a high degree of 
similarity with BMP signaling. Furthermore, the function and potency of these two proteins 
within the context of an EC in a developing blood vessel sprout remain unclear. It is therefore 
hypothesized that PMEPA1 and SMAD7 inhibit BMP signaling and BMP-dependent 
angiogenesis in EC. The role of PMEPA1 and SMAD7 in BMP signaling will first be studied, 
potentially elucidating novel components of BMP regulation in endothelial cells, followed by an 
exploration of their role in 3-dimensional sprouting angiogenesis. It is important to gather an 
understanding of various inhibitors of BMP signaling, since as previously discussed, mis-
regulation of BMP signaling has significant physiological consequences.  
 
Methods 
2-D Immunofluorescence Analysis 
Human umbilical vein endothelial cells (HUVEC) (Lonza) were transfected overnight 
with non-targeting (NT) siRNA or targeting locked nucleic acid siRNAs (Thermo Fisher 
SMAD7 s8413; Thermo Fisher PMEPA1 s32432) at 10 nM each using Lipofectamine 
RNAiMAX (Thermo Fisher) according to the manufacturer's recommendations. Following 
transfection, cells were trypsinized and plated at 20,000 cells/cm2 onto 0.1% gelatin-coated 
coverslips and allowed to adhere overnight (6 coverslips per knockdown). Remaining HUVEC 
were plated onto 60 mm tissue culture plates to collect protein the following day to confirm 
knockdown (KD) via Western Blot (WB). The next day, cells were pre-treated in low-serum 
OptiMEM (Life Technologies) + 0.1% Newborn Bovine Calf Serum (NBCS) for four hours. 
Cells were then treated for 90 minutes with either BMP6 (R&D Systems) at 100 ng/mL or 
vehicle (4mM HCl + 0.5% BSA) percent matched to the dose of BMP6 (3 coverslips per 
treatment per knockdown). Following treatment, cells were fixed and permeabilized with 4% 
PFA for 10 minutes at room temperature and 0.5% Triton X for 20 minutes at room temperature 
respectively, followed by an overnight 4˚C incubation in block solution (1% BSA, 5% Goat 
Serum, 0.3% Triton X in Dulbecco’s PBS (DPBS)). Coverslips were then incubated overnight 
again in a 1:1000 dilution of rabbit monoclonal antibody against pSMAD1/5 (Cell Signaling). 
Cells were washed three times for 5 minutes with PBS and then incubated in secondary antibody 
at room temperature for two hours (1:250 Alexafluor 488-conjugated Goat anti-Rabbit and 1:100 
Alexafluor 594-conjugated phalloidin; Life Technologies and Invitrogen, respectively). 
Following secondary incubation, cells were washed three times for 5 minutes with PBS, with the 
third wash containing 1:1000 DRAQ7 nuclear stain (Abcam). Coverslips were then mounted on 
slides and imaged for phalloidin, pSMAD1/5, and DRAQ7 fluorescence, followed by analysis of 
fluorescent intensities using Image J. pSMAD fluorescence was statistically analyzed across 
conditions via a one-way ANOVA and Tukey’s post hoc with an alpha of 0.05. 
 
3-D Microcarrier Bead Assay 
BMP-dependent sprouting and branching were analyzed via a 3-D microcarrier bead 
assay. Low passage HUVEC (P2-P4) transfected in the same manner as described previously 
were coated onto cytodex beads. Knockdown was confirmed via qPCR. Cytodex beads were 
resuspended at a concentration of 500 beads/mL in a 2 mg/mL fibrinogen solution and added to a 
24 well plate containing 0.625 units/mL thrombin and allowed to clot (Day 0). Fibroblasts were 
then seeded onto the fibrin gel at 20,000 cells/well. Cells were treated with 200 ng/mL BMP6 or 
control daily from days 2-6. Day 6 beads were trypsinized (0.125%, or 2.5x TE) at room 
temperature to remove fibroblasts, fixed in 4% PFA for 15 minutes and permeabilized with 0.5% 
Triton X for 2 hours at room temperature. The cells were then blocked overnight to prevent 
nonspecific protein binding, followed by a three hour incubation in 1:1000 DRAQ7 and 1:50 
Alexafluor 488 conjugated Phalloidin. Beads were then rinsed 3x5 minutes with PBS and 
imaged. The number of sprouts emerging per bead, the total length of vessels per bead, and the 
number of branches per mm of vessel length were analyzed using Image J image analysis 
software (NIH). The number of branches per mm across conditions was statistically analyzed 
using a one-way ANOVA followed by Tukey’s post hoc with an alpha of 0.05.  
Notch Manipulation 
Notch signaling was stimulated in HUVEC via Fc-conjugated Dll4. 4 x 60 mm plates 
were coated with recombinant protein G (Invitrogen) for 30 minutes at room temperature and 
then and either 10 ug/mL Fc-conjugated Dll4 or IgG (2 plates per condition; Adipogen and 
Invitrogen, respectively). HUVEC were then plated onto these dishes and incubated for 48 hours 
at 37˚C. Notch signaling was inhibited via DAPT (Cayman Chemical). HUVEC were plated onto 
60 mm tissue culture dishes and at 80% confluency were treated with 5 µM DAPT or vehicle 
control DMSO for 24 hours at 37˚C. For each condition, one plate was collected for RNA and 
the other for protein analysis. Analysis of PMEPA1 and SMAD7 expression levels was done by 
western blot and qPCR. 
 
Western Blotting 
 Whole cell lysate was collected in RIPA buffer with a 1:100 dilution of protease-
phosphatase inhibitor cocktail and reduced in 100 mM DTT for 15 minutes at 100˚C. 10 µg of 
protein was loaded onto a TGF Stain Free FastCast gel. The gel was activated for 1 minute under 
UV light and then transferred onto PVDF membrane. The membrane was imaged under UV light 
to observe total protein per well and then blocked for one hour in 5% blotting-grade blocker 
dissolved in 0.1% Tween-20 in DPBS (PBST). Membrane was incubated overnight in 1% 
blotting-grade blocker in PBST in a 1:500 primary antibody dilution for PMEPA1 (rabbit 
polyclonal; Abnova PAB17430) and a 1:2000 dilution for SMAD7 (mouse monoclonal; Abcam 
ab55493). The following day, membrane was rinsed 3 times with PBST followed by three 5 
minute washes in PBST, followed by a one hour incubation in horseradish peroxidase-
conjugated secondary antibody at a 1:2000 dilution in 1% blotting-grade blocker in PBST. The 
membrane was then rinsed and washed again in PBST as described previously, and then covered 
with Luminata Forte western HRP substrate (EMD Millipore) for 30 seconds before imaging 
under UV light. The amount of PMEPA1 and SMAD7 protein was normalized to total protein 
using Image Lab software. 
 
Quantitative Real-Time PCR 
qPCR was conducted as previously described,6 with the exception that SybrGreen real-time PCR 
was performed on the QuantStudio 6 Flex Real-TIme PCR System (Thermo Fisher) and raw CT 
values were normalized to GAPDH. Primer sequences are as follows: 
Gene Forward primer (5’ → 3’) Reverse primer (5’ → 3’) Vendor Catalog Number 
hGAPDH Proprietary sequence Proprietary sequence BioRad qHsaCID0038674 
hHes1 ATCTGAGCACAGAAAGTCATCAAAG GGATGCTCTGAAGAAAGATAGCTC N/A N/A 
hPMEPA1 CAACTGCAAACGCTCTTTGTT ACCACGATGATGATGATCTGAAC N/A N/A 





Figure 1: SMAD7 does not significantly affect EC responsiveness to BMP6.  
A-B: HUVEC transfected with non-targeting siRNA. N = 178. 
C: HUVEC transfected with SMAD7 siRNA. N = 59. 
D-E: HUVEC transfected with non-targeting siRNA and treated with 100 ng/mL BMP6. N = 152. Cells show increased pSMAD 
nuclear localization as compared to control (B). 
F: HUVEC transfected with SMAD7 siRNA and treated with 100 ng/mL BMP6. N = 135. Cells show increased pSMAD nuclear 
localization as compared to control (C). 
G: SMAD7 KD does not significantly increase BMP responsiveness. pSMAD nuclear fluorescence was compared across all 
conditions using a one way ANOVA with an alpha of 0.05 followed by Tukey’s Post Hoc. 
H-I: Western Blot and quantification for SMAD7 protein to confirm KD. EC transfected with s8413 showed an 86% reduction in 
SMAD7 protein.  
 
Figure 2: PMEPA1 knockdown significantly increases EC responsiveness to BMP6.  
A-B: HUVEC transfected with non-targeting siRNA. N = 223. 
C: HUVEC transfected with PMEPA1 siRNA. N = 267. 
D-E: HUVEC transfected with non-targeting siRNA and treated with 100 ng/mL BMP6. N = 226. Cells show increased pSMAD 
nuclear localization as compared to control (B). 
F: HUVEC transfected with PMEPA1 siRNA and treated with 100 ng/mL BMP6. N = 159. Cells show increased pSMAD nuclear 
localization as compared to control (C). 
G: PMEPA1 KD significantly increases BMP responsiveness. pSMAD nuclear fluorescence was compared across all conditions 
using a one way ANOVA with an alpha of 0.05 followed by Tukey’s Post Hoc. “****” indicates p-value <0.0001 
H-I: Western Blot and quantification for PMEPA1 protein to confirm KD. EC transfected with s32432 showed a 92% reduction in 
PMEPA1 protein.  
 
 
Figure 3: Expression of PMEPA1 and SMAD7 are regulated by Notch. 
A: qPCR for Hes1, SMAD7, and PMEPA1 upon Notch gain of function (Dll4) or Notch loss of function (DAPT) showed that all genes 
are upregulated upon Dll4 treatment and downregulated upon DAPT treatment. mRNA expression levels were normalized to 
GAPDH. mRNA fold change of cells treated with Dll4 was normalized to IgG control and cells treated with DAPT was normalized to 




Figure 4: PMEPA1 and SMAD7 KD in the 3-D Microcarrier Bead Assay 
A-C: HUVEC transfected with non-targeting, PMEPA1, or SMAD7 siRNAs, respectively, were coated on a cytodex microcarrier bead 
and embedded in a fibrin matrix. Beads were stained with Phalloidin and depth-encoded using Fiji software. N = 8,9,9, respectively. 
D-F: HUVEC transfected with non-targeting, PMEPA1, or SMAD7 siRNAs, respectively, were coated on a cytodex microcarrier 
bead, embedded in a fibrin matrix, and treated with 200 ng/mL BMP6. N = 9,9,9, respectively. 
G: Neither PMEPA1 nor SMAD7 KD significantly increased number of branches formed per mm of vessel length. Branches/mm was 
compared across all conditions using a one-way ANOVA with an alpha of 0.05 followed by Tukey’s Post Hoc. “*” indicates p-value 
<0.05. 
H: qRT-PCR to confirm KD of PMEPA1 and SMAD7, respectively. EC transfected with s32432 showed a 77% reduction in PMEPA1 
mRNA and EC transfected with s8413 showed a 31% reduction in SMAD7 mRNA.  
 
  
SMAD7 does not significantly affect EC responsiveness to BMP6 
        SMAD7, an inhibitory SMAD protein, is known to inhibit TGFβ signaling; however, its 
role in BMP signaling in endothelial cells is unknown. Due to the parallel pathway structure 
between TGFβ signaling and BMP signaling and the fact that SMAD7 has been implicated as an 
inhibitor of BMP signaling before, it was hypothesized that SMAD7 knockdown would lead to 
significantly increased pSMAD nuclear localization in HUVEC compared to control. To address 
this, the effect of SMAD7 on BMP responsiveness was determined via knockdown and 
subsequent analysis of nuclear localization of a downstream target of active BMP signaling, 
pSMAD. HUVEC were transfected with either a non-targeting siRNA or a siRNA against 
SMAD7 and then treated with BMP6. Effects on pSMAD nuclear localization were observed 
with a confocal microscope and quantified using Fiji software. Treatment with BMP6 
significantly increased pSMAD nuclear localization as compared to cell treated with vehicle 
control (Figure 1 B,E). Following BMP treatment, knockdown of SMAD7 did not alter nuclear 
pSMAD localization levels as compared to control (Figure 1C,F,G). An 86% knockdown of 
SMAD7 was validated by western blot (Figure 1H,I). This suggests that in endothelial cells, 
SMAD7 does not have an effect on BMP signaling. 
 
PMEPA1 knockdown significantly increases EC responsiveness to BMP6 
        PMEPA1, like SMAD7, has been shown to inhibit TGFβ signaling, and its role in BMP 
signaling in EC also needs to be determined. It was hypothesized that knockdown of PMEPA1 
would result in significantly increased pSMAD nuclear localization in HUVEC. In a manner 
reflecting the protocol discussed previously for SMAD7, HUVEC were transfected with a 
siRNA against PMEPA1, treated with BMP6, and imaged to observe changes in pSMAD nuclear 
localization. Treatment with BMP6 significantly increased the fluorescent intensity of nuclear 
pSMAD (Figure 2B,E). Knockdown of PMEPA1 significantly increased the amount of pSMAD 
nuclear localization even further as compared to control (Figure 2C,F,G). A 92% knockdown of 
PMEPA1 was confirmed via western blot (Figure 2H,I). This validates that PMEPA1 inhibits 
BMP signaling in endothelial cells. 
 
Expression levels of SMAD7 and PMEPA1 are regulated by Notch 
A previous screen of the expression levels of various TGFβ and BMP signaling members 
upon Notch induction showed that SMAD7 and PMEPA1 expression levels were significantly 
upregulated. This effect of Notch on SMAD7 and PMEPA1 was validated with a Notch gain-of-
function and loss-of-function experimental approaches. To test Notch gain-of-function, HUVEC 
were seeded on plates with Fc-conjugated Dll4 or IgG. To test Notch loss-of-function, HUVEC 
were seeded on plates and then treated with either DAPT or DMSO vehicle control. qPCR was 
used to determine the fold change of SMAD7, PMEPA1, and Hes1 (a known downstream target 
of Notch signaling used as a positive control) mRNA, normalized to the housekeeping gene 
GAPDH. Ongoing experiments are being conducted to determine the fold change in protein 
levels via western blot. Both SMAD7 and PMEPA1 showed an increased fold change (2.00 and 
1.77 respectively) in mRNA expression in a manner similar to the known Notch target Hes1. 
When treated with DAPT, SMAD7 and PMEPA1 expression was down 1.74 and 1.36 fold, 




PMEPA1 and SMAD7 KD in the 3-D Microcarrier Bead Assay 
 Preliminary results from experiments designed to test the effect of SMAD7 and PMEPA1 
knockdown EC in a 3-D vessel formation assay show that neither knockdown has a significant 
effect on sprouting angiogenesis (Figure 4). However, EC transfected with siRNA against 
PMEPA1 showed delayed sprouting from the bead by two experimental days, as observed by the 
decreased vessel length in beads with PMEPA1 knockdown (Figure 4B,E). To conclude, 
PMEPA1 seems to be required for angiogenesis due to delayed sprouting upon knockdown, 
while SMAD7 has no effect on angiogenesis with BMP stimulation.   
 
Discussion 
The effect of SMAD7 on pSMAD nuclear localization is not consistent with its purported 
role as an inhibitor of BMP signaling. However, its exact role in endothelial cells has not been 
extensively studied and its role within the context of a sprouting vessel still remains to be 
determined. To suppress TGFβ signaling, inhibitory SMADs act in a variety of ways, including 
binding to receptors and targeting them for degradation.1,9 SMAD6, a confirmed inhibitor of 
BMP signaling in EC, binds to BMP Type I receptor through its Mad Homology 2 (MH2) 
domain. However, SMAD7 acts differently since the N-terminus is also required for increasing 
the affinity of the MH2 domain for the receptor. In addition, the MH2 domain of SMAD6 and 
SMAD7 is poorly conserved (Figure 5). Since this region is critical in receptor-iSMAD 
interaction, it is possible that this difference affects SMAD6/7 binding affinity, and thus, 
suppressive ability, for BMP receptors.4 Thus far, these results indicate that SMAD7’s role in EC 
specifically may not be as significant as that of other BMP inhibitors such as SMAD6.  
 
 
Figure 5: The structure of SMAD6 and SMAD7. The MH2 domain of the inhibitory SMADs, which binds to BMP receptors to inhibit 
downstream signaling, is poorly conserved. 
 
Contrary to SMAD7, PMEPA1 inhibits TGFβ signaling by sequestering intracellular 
RSMADs and preventing their activation.9 It was hypothesized that PMEPA1 has the ability to 
also inhibit BMP signaling due to the structural similarity of SMAD2/3 of TGFβ signaling with 
SMAD1/5/8 of BMP signaling. In SMAD2/3, one residue, Trp368, is necessary for PMEPA1 
binding.9 In SMAD1/5/8, at the same amino acid number 368, the residue is a phenylalanine 
instead of a tryptophan, a similar nonpolar aromatic side chain. Thus, it is possible that PMEPA1 
is able to bind to SMAD1/5/8 at this residue due to the structural similarity of the side chains. 
Knockdown of PMEPA1 via si32432 resulted in a significant increase in pSMAD nuclear 
localization upon BMP treatment (p < 0.0001, alpha = 0.05), likely due to the fact that PMEPA1 
may also bind SMAD1/5/8. Since my data show that PMEPA1 KD upregulates BMP signaling 
in EC, PMEPA1 KD HUVEC are predicted to exhibit altered branching compared to controls. 
However, it was not possible to clearly assess effects of PMEPA1 KD on sprouting because, to 
my surprise, this manipulation produced delayed sprouting. This phenotype may be due to the 
role of PMEPA1 in TGFβ signaling. TGFβ signaling is required for proper capillary 
morphogenesis via induction of apoptosis, a process required for vessel lumen formation and 
pruning of the mature vessel network.2,3,7 Knockdown of PMEPA1, a TGFβ inhibitor, may 
increase TGFβ-mediated apoptosis in EC, which may explain the delayed sprouting phenotype. 
However, these results are preliminary and the experiment needs to be repeated to confirm this 
PMEPA1 knockdown phenotype and achieve better knockdown of SMAD7. 
PMEPA1 has the potential to regulate BMP-dependent angiogenesis and can therefore 
potentially be manipulated as a potential therapeutic target for diseases such as PAH, CCM, and 
HHT. All of these pathologies result from aberrant BMP signaling, and thus, the regulation of a 
BMP inhibitor via knockdown or exogenous introduction could potentially mitigate the effects of 
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